28 patents
Utility
Antibodies and Methods for Treatment of Influenza a Infection
26 Oct 23
The present disclosure provides antibodies that neutralize infection of influenza A virus.
Davide Corti, Michael Alexander Schmid
Filed: 7 Dec 21
Utility
Antibodies Against SARS-COV-2 and Methods of Using the Same
19 Oct 23
The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection.
Davide CORTI, Katja FINK, Martina BELTRAMELLO, Elisabetta CAMERONI, Dora PINTO, Gyorgy SNELL, Florian A. LEMPP, Amalio TELENTI
Filed: 14 Sep 22
Utility
Neutralizing anti-influenza b antibodies and uses thereof
17 Oct 23
The invention relates to antibodies and antigen binding fragments thereof that are capable of binding to influenza B virus hemagglutinin (HA) and neutralizing influenza B virus in two phylogenetically distinct lineages.
Nicole Kallewaard-Lelay, Qing Zhu, Ebony Benjamin, Leslie Wachter, Andy Yuan, Josephine Mary Mcauliffe, Davide Corti, Antonio Lanzavecchia
Filed: 12 Oct 21
Utility
Antibodies That Potently Neutralize Hepatitis B Virus and Uses Thereof
28 Sep 23
The present invention relates to antibodies, and antigen binding fragments thereof, that bind to the antigenic loop region of hepatitis B surface antigen (HBsAg) and potently neutralize infection of both hepatitis B virus (HBV) and hepatitis delta virus (HDV).
Davide CORTI
Filed: 18 Jul 22
Utility
Predictive Universal Signatures for Multiple Disease Indications
7 Sep 23
Universal signatures represent generalizable features that are informative for generating predictions for different disease activities across different diseases.
Amalio Telenti, Julia Di Iulio
Filed: 6 Aug 21
Utility
Broadly neutralizing antibodies directed against the rabies virus glycoprotein and uses thereof
22 Aug 23
The invention relates to antibodies, and antigen binding fragments thereof, that potently neutralize infection of both RABV and non-RABV lyssaviruses.
Davide Corti, Hervé Bourhy
Filed: 22 May 20
Utility
Broadly neutralizing antibodies directed against the rabies virus glycoprotein and uses thereof
15 Aug 23
The invention relates to antibodies, and antigen binding fragments thereof, that potently neutralize infection of both RABV and non-RABV lyssaviruses.
Davide Corti, Hervé Bourhy
Filed: 22 May 20
Utility
Engineered Hepatitis B Virus Neutralizing Antibodies and Uses Thereof
3 Aug 23
The present disclosure relates, in part, to antibodies, and antigen-binding fragments thereof, that can bind to the antigenic loop region of hepatitis B surface antigen (HBsAg) and, optionally, can neutralize infection hepatitis B virus (HBV), and further optionally, of hepatitis delta virus (HDV).
Elisabetta CAMERONI, Davide CORTI, Nadine CZUDNOCHOWSKI, Florian A. LEMPP, Laura ROSEN, Gyorgy SNELL
Filed: 23 Jun 21
Utility
Treatment of Respiratory Virus Infection by Modulation of the N-glycosylation Pathway
6 Jul 23
The present disclosure relates to methods of inhibiting replication of a respiratory virus, and methods of treating or preventing a respiratory virus infection in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a N-glycosylation pathway inhibitor.
Dale R. Balce, Istvan Bartha, Johannes Grosse, Seungmin Hwang, Zachary Newby, Arnold Park, Leah B. Soriaga, Amalio Telenti, Winston C. Tse
Filed: 16 Dec 22
Utility
HIV vaccines comprising one or more population episensus antigens
18 Apr 23
Provided herein are HIV-1 vaccines comprising a carrier and a population episensus antigen determined using the EpiGraph approach.
Eric Bruening, Klaus Frueh, Louis Picker, Bette T. M. Korber, James Theiler, Emily Marshall
Filed: 31 Aug 20
Utility
ANTI-O2 Antibodies and Uses Thereof
16 Mar 23
The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to Klebsiella pneumoniae O2 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae) and/or protects mice from a lethal Klebsiella challenge.
Qun WANG, Meghan PENNINI, Xiaodong XIAO, Davide CORTI, Elisabetta CAMERONI, Martina BELTRAMELLO, Gilad KAPLAN, Anna DeMARCO, Charles K. Stover
Filed: 11 Aug 22
Utility
Antibodies Binding to Plasmodium Circumsporozoite Protein and Uses Thereof
16 Mar 23
The present invention provides antibodies targeting Plasmodium sporozoites, in particular plasmodium circumsporozoite protein.
Davide CORTI, Luca PICCOLI, Katja FINK, Elisabetta CAMERONI
Filed: 30 Apr 20
Utility
HIV vaccines comprising one or more population episensus antigens
17 Jan 23
Provided herein are HIV-1 vaccines comprising a carrier and a population episensus antigen determined using the EpiGraph approach.
Eric Bruening, Klaus Frueh, Louis Picker, Bette T. M. Korber, James Theiler, Emily Marshall
Filed: 31 Aug 20
Utility
Antibody Compositions and Methods for Treating Hepatitis B Virus Infection
1 Dec 22
The present disclosure relates to pharmaceutical compositions that comprise an antibody that neutralizes infection of hepatitis B virus (HBV).
Phillip S. PANG, Erik MOGALIAN, Lynn E. CONNOLLY, Jonathan GALL
Filed: 28 Aug 20
Utility
Compositions and Methods for Treating Hepatitis B Virus (HBV) Infection
27 Oct 22
The present disclosure provides methods for treating HBV infection using an siRNA that targets an HBV gene.
Phillip S. Pang, Anna Bakardjiev, Lynn E. Connolly
Filed: 12 May 20
Utility
Antibodies against SARS-CoV-2 and methods of using the same
25 Oct 22
The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection.
Davide Corti, Katja Fink, Martina Beltramello, Elisabetta Cameroni, Dora Pinto, Gyorgy Snell, Florian A. Lempp, Amalio Telenti
Filed: 23 Jul 21
Utility
Compositions and Methods for Treatment of Influenza a Infection
29 Sep 22
The present disclosure provides antibodies, antibody compositions, and methods for use in prophylaxis and treatment of influenza A infection.
Phillip S. PANG, Lynn E. CONNOLLY, Erik MOGALIAN
Filed: 28 Aug 20
Utility
Hepatitis B Virus Vaccines
15 Sep 22
The present disclosure relates to isolated polynucleotides and polypeptides, and related hepatitis B virus (HBV)vaccines.
Eric BRUENING, Janet DOUGLAS, Emily MARSHALL, Karina YUSIM, Bette KORBER, James THEILER
Filed: 28 Aug 20
Utility
Coronavirus Irna Compositions and Methods of Use Thereof
28 Apr 22
The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the coronavirus genome.
Akin Akinc, James D. McIninch, Yesseinia Anglero-Rodriguez, Mark K. Schlegel, Christy M. Hebner, Florian A. Lempp
Filed: 10 Nov 21
Utility
Combination HBV Therapy
24 Feb 22
The present disclosure provides methods for treating HBV infection using combination therapies, and related kits and compositions for use.
Anna Bakardjiev, Phillip S. Pang, Davide Corti
Filed: 19 Dec 19